GB9501040D0
(en)
*
|
1995-01-19 |
1995-03-08 |
Quadrant Holdings Cambridge |
Dried composition
|
US8183344B2
(en)
*
|
1996-04-24 |
2012-05-22 |
University Of Michigan |
Inactivation resistant factor VIII
|
US6475725B1
(en)
*
|
1997-06-20 |
2002-11-05 |
Baxter Aktiengesellschaft |
Recombinant cell clones having increased stability and methods of making and using the same
|
US6528286B1
(en)
*
|
1998-05-29 |
2003-03-04 |
Genentech, Inc. |
Mammalian cell culture process for producing glycoproteins
|
AUPP521298A0
(en)
*
|
1998-08-12 |
1998-09-03 |
Life Therapeutics Limited |
Purification of fibrinogen
|
US6358703B1
(en)
|
1998-12-10 |
2002-03-19 |
Bayer Corporation |
Expression system for factor VIII
|
AUPP790698A0
(en)
|
1998-12-23 |
1999-01-28 |
Life Therapeutics Limited |
Separation of microorganisms
|
AUPP790898A0
(en)
|
1998-12-23 |
1999-01-28 |
Life Therapeutics Limited |
Renal dialysis
|
US20050224355A1
(en)
*
|
1999-12-23 |
2005-10-13 |
Brendon Conlan |
Removal of biological contaminants
|
AUPP971399A0
(en)
|
1999-04-12 |
1999-05-06 |
Life Therapeutics Limited |
Separation of plasma components
|
AT409379B
(de)
|
1999-06-02 |
2002-07-25 |
Baxter Ag |
Medium zur protein- und serumfreien kultivierung von zellen
|
JP4674021B2
(ja)
*
|
1999-07-13 |
2011-04-20 |
ビオヴィトルム・アクチボラゲット(プブリクト) |
安定第viii因子組成物
|
US6767741B1
(en)
*
|
1999-08-27 |
2004-07-27 |
Invitrogen Corporation |
Metal binding compounds and their use in cell culture medium compositions
|
DE60041573D1
(de)
|
1999-08-31 |
2009-04-02 |
Sony Computer Entertainment Inc |
Unterhaltungssystem, aufzeichnungsmdeium und programm
|
US7077942B1
(en)
*
|
1999-12-23 |
2006-07-18 |
Gradipore Limited |
Removal of biological contaminants
|
AUPQ691400A0
(en)
|
2000-04-14 |
2000-05-11 |
Life Therapeutics Limited |
Separation of micromolecules
|
AUPQ697300A0
(en)
*
|
2000-04-18 |
2000-05-11 |
Life Therapeutics Limited |
Separation apparatus
|
ATE449200T1
(de)
|
2000-04-18 |
2009-12-15 |
Gradipore Ltd |
Trennung und behandlung von proben durch elektrophorese
|
US6923896B2
(en)
*
|
2000-09-22 |
2005-08-02 |
The Texas A&M University System |
Electrophoresis apparatus and method
|
CN1235667C
(zh)
*
|
2000-10-06 |
2006-01-11 |
格拉迪普有限公司 |
多口分离装置及方法
|
AUPR222300A0
(en)
*
|
2000-12-21 |
2001-01-25 |
Life Therapeutics Limited |
Electrophoresis device and method
|
US7220718B2
(en)
|
2001-08-03 |
2007-05-22 |
United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Oral treatment of hemophilia
|
EP2298354B1
(de)
|
2001-10-10 |
2014-03-19 |
ratiopharm GmbH |
Neumodulierung und Glykokonjugation von Interferon-beta
|
KR20040065278A
(ko)
*
|
2001-12-21 |
2004-07-21 |
노보 노르디스크 에이/에스 |
변경된 인자 ⅶ 폴리펩티드의 액체 조성물
|
BR0215216A
(pt)
|
2001-12-21 |
2004-11-16 |
Novo Nordisk Healthcare Ag |
Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
|
US20040009918A1
(en)
*
|
2002-05-03 |
2004-01-15 |
Hanne Nedergaard |
Stabilised solid compositions of modified factor VII
|
KR101212025B1
(ko)
|
2002-06-21 |
2013-01-09 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
인자 ⅶ 폴리펩티드의 안정화된 고체 조성물
|
AU2003249990B2
(en)
|
2002-07-09 |
2007-06-28 |
Takeda Pharmaceutical Company Limited |
Animal protein free media for cultivation of cells
|
EP2572732A1
(de)
|
2003-02-26 |
2013-03-27 |
Nektar Therapeutics |
Konjugate mit Polymer-Faktor-VIII-Anteil
|
CA2518327A1
(en)
*
|
2003-03-18 |
2004-09-30 |
Novo Nordisk Health Care Ag |
Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
|
US7897734B2
(en)
*
|
2003-03-26 |
2011-03-01 |
Novo Nordisk Healthcare Ag |
Method for the production of proteins
|
AU2004241698A1
(en)
*
|
2003-05-23 |
2004-12-02 |
Novo Nordisk Health Care Ag |
Protein stabilization in solution
|
ES2382157T3
(es)
*
|
2003-06-25 |
2012-06-05 |
Novo Nordisk Health Care Ag |
Composición líquida de polipépttidos del factor VII
|
ATE446768T1
(de)
*
|
2003-07-01 |
2009-11-15 |
Novo Nordisk Healthcare Ag |
Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
|
EP1656158B1
(de)
*
|
2003-08-14 |
2016-03-09 |
Novo Nordisk Health Care AG |
Flüssige, wässrige pharmazeutische zusammensetzung von faktor-vii-polypeptiden
|
MXPA06006886A
(es)
*
|
2003-12-19 |
2006-09-04 |
Novo Nordisk Healthcare Ag |
Composiciones estabilizadas de polipeptidos del factor vii.
|
GB0414825D0
(en)
|
2004-07-02 |
2004-08-04 |
Biostatus Ltd |
Gel formulations and uses thereof
|
US7422875B2
(en)
*
|
2004-07-20 |
2008-09-09 |
Board Of Regents Of The University Of Nebraska |
Compositions and methods for increasing protein production
|
US20060094104A1
(en)
|
2004-10-29 |
2006-05-04 |
Leopold Grillberger |
Animal protein-free media for cultivation of cells
|
WO2006050050A2
(en)
*
|
2004-10-29 |
2006-05-11 |
Centocor, Inc. |
Chemically defined media compositions
|
CA2594580C
(en)
*
|
2005-01-25 |
2013-09-24 |
Wyeth Research Ireland Limited |
Method for diafiltration
|
EP1707634A1
(de)
*
|
2005-03-29 |
2006-10-04 |
Octapharma AG |
Verfahren zur Isolierung von rekombinant hergestellten Proteinen
|
US20070212770A1
(en)
*
|
2006-01-04 |
2007-09-13 |
Baxter International Inc. |
Oligopeptide-free cell culture media
|
US20090203077A1
(en)
*
|
2006-06-30 |
2009-08-13 |
The Regents Of The University Of Michigan |
Method of producing factor viii proteins by recombinant methods
|
WO2008005847A2
(en)
*
|
2006-06-30 |
2008-01-10 |
The Regents Of The University Of Michigan |
Method of producing factor viii proteins by recombinant methods
|
DK2126106T3
(en)
|
2007-02-23 |
2017-12-04 |
Sk Chemicals Co Ltd |
Process for the preparation and purification of Factor VIII and its derivatives
|
RU2469739C2
(ru)
*
|
2007-04-26 |
2012-12-20 |
БАЙЕР ХЕЛСКЕА ЛЛСи |
Стабилизация жидких растворов рекомбинантного белка для хранения в замороженном состоянии
|
BRPI0818913A2
(pt)
*
|
2007-11-01 |
2015-05-12 |
Univ Rochester |
Fator viii recombinante tendo elevada estabilidade
|
SG10201503304RA
(en)
*
|
2007-12-27 |
2015-06-29 |
Baxter Int |
Cell culture processes
|
DE102008051574A1
(de)
|
2008-10-14 |
2010-04-15 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Verfahren zur Herstellung von Interferon-beta und deren Varianten
|
JP5719301B2
(ja)
*
|
2008-11-12 |
2015-05-13 |
バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated |
血清不含インスリン不含で第vii因子を産生する方法
|
KR101574056B1
(ko)
|
2009-07-31 |
2015-12-02 |
백스터 인터내셔널 인코포레이티드 |
Adamts 단백질 발현을 위한 세포 배양 배지
|
ES2865250T3
(es)
|
2009-09-21 |
2021-10-15 |
Takeda Pharmaceuticals Co |
Formulaciones de ADAMTS13 líquidas y liofilizadas estabilizadas
|
CN102648212B
(zh)
|
2009-11-13 |
2014-12-03 |
基立福疗法公司 |
包含冯维勒布兰德因子(vWF)的制剂及其相关制备方法、试剂盒和用途
|
MX2012012526A
(es)
|
2010-04-26 |
2012-11-23 |
Novartis Ag |
Medio de cultivo celular mejorado.
|
BR112013000512A2
(pt)
|
2010-07-08 |
2016-05-17 |
Baxter Healthcare Sa |
método para produzir uma composição de adamts 13 (ra13) recombinante, sobrenadante de cultura de célula, e , composição adamts13 recombinante (ra13)'
|
GB201014121D0
(en)
*
|
2010-08-24 |
2010-10-06 |
Univ Gent |
Particulate biologic drug delivery system
|
EP2702077A2
(de)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
|
RU2592680C2
(ru)
*
|
2011-04-29 |
2016-07-27 |
Биокон Рисерч Лимитед |
Способ снижения накопления лактата при культивировании и способ получения антитела
|
DK3626737T3
(da)
|
2011-05-13 |
2024-02-05 |
Octapharma Ag |
Fremgangsmåde til at forøge produktiviteten af eukaryote celler i produktionen af rekombinant fviii
|
AU2012324020A1
(en)
|
2011-12-30 |
2013-07-18 |
Grifols, S.A. |
Method for purifying Factor VIII
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
SG11201507230PA
(en)
|
2013-03-12 |
2015-10-29 |
Abbvie Inc |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
US9677105B2
(en)
|
2013-03-14 |
2017-06-13 |
Momenta Pharmaceuticals, Inc. |
Methods of cell culture
|
US9217168B2
(en)
|
2013-03-14 |
2015-12-22 |
Momenta Pharmaceuticals, Inc. |
Methods of cell culture
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
US8956830B2
(en)
|
2013-03-14 |
2015-02-17 |
Momenta Pharmaceuticals, Inc. |
Methods of cell culture
|
US20140271622A1
(en)
*
|
2013-03-14 |
2014-09-18 |
Momenta Pharmaceuticals, Inc. |
Methods of cell culture
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
EP3052640A2
(de)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
CA2942770A1
(en)
*
|
2014-03-23 |
2015-10-01 |
Advantech Bioscience Farmaceutica Ltda. |
Enhancement of recombinant protein expression with copper
|
KR102352250B1
(ko)
|
2014-03-25 |
2022-01-17 |
제넨테크, 인크. |
세포 배양 배지에 사용하기 위한 폴록사머를 제조하는 방법
|
MX2016012870A
(es)
|
2014-04-01 |
2017-05-12 |
Advantech Bioscience Farmacêutica Ltda |
Formulaciones de factor viii estables con bajo tenor de azucar - glicina.
|
US9855319B2
(en)
|
2014-04-01 |
2018-01-02 |
Advantech Bioscience Farmacêutica Ltda |
Stabilization of factor VIII without calcium as an excipient
|
JP6917984B2
(ja)
*
|
2016-05-09 |
2021-08-11 |
協和発酵バイオ株式会社 |
培地、アルブミン非含有培地用添加剤および多能性幹細胞の培養方法
|
EP3625329A1
(de)
*
|
2017-05-17 |
2020-03-25 |
Octapharma AG |
Verfahren zur herstellung eines rekombinanten zielproteins
|
PL3781943T3
(pl)
|
2018-04-20 |
2022-08-01 |
Janssen Biotech, Inc |
Kwalifikacja kolumny chromatograficznej w sposobach produkcji w celu wytwarzania kompozycji przeciwciał anty-il12/il23
|
MA54248A
(fr)
|
2018-11-13 |
2021-09-22 |
Janssen Biotech Inc |
Régulation de métaux traces pendant la production d'anticorps anti-cd38
|
CN113825765A
(zh)
|
2019-03-14 |
2021-12-21 |
詹森生物科技公司 |
用于制备抗il12/il23抗体组合物的制造方法
|
US20220153830A1
(en)
|
2019-03-14 |
2022-05-19 |
Janssen Biotech, Inc. |
Manufacturing Methods for Producing Anti-TNF Antibody Compositions
|
MY193349A
(en)
|
2019-12-06 |
2022-10-06 |
Regeneron Pharma |
Anti-vegf protein compositions and methods for producing the same
|
BR112022019817A2
(pt)
|
2020-04-02 |
2022-12-06 |
Takeda Pharmaceuticals Co |
Variante de adamts13, composições e usos das mesmas
|
WO2023281463A1
(en)
|
2021-07-09 |
2023-01-12 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
IL309987A
(en)
|
2021-07-09 |
2024-03-01 |
Janssen Biotech Inc |
Production methods for the production of anti-IL12/IL23 antibody compositions
|
US20230332084A1
(en)
|
2022-03-02 |
2023-10-19 |
Regeneron Pharmaceuticals, Inc. |
Bioreactor for antibody production
|